Omeros Corp (OMER):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Omeros Corp (OMER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9800
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s pipeline products include Omidria, a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders, among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Omeros Corp (OMER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omeros Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Omeros Corp, Medical Devices Deals, 2012 to YTD 2018 9
Omeros Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omeros Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Omeros Acquires Antibody Related Assets from Xori 11
Licensing Agreements 12
Omeros Enters into Licensing Agreement with Fagron 12
Equity Offering 13
Omeros Raises USD68.3 Million in Public Offering of Shares 13
Omeros Raises USD0.74 Million in Public Offering of Shares 15
Omeros Raises USD37.3 Million in Public Offering of Shares 16
Omeros Raises USD84 Million in Public Offering of Shares and Pre-Funded Warrants 18
Omeros Completes Public Offering Of Shares For US$40.3 Million 20
Omeros Completes Private Placement Of Common Stock For US$16 Million 22
Omeros Announces Public Offering Of Common Stock For US$60 Million 24
Omeros Completes Public Offering Of Common Stock For US$34.5 Million 25
Omeros Corp – Key Competitors 27
Omeros Corp – Key Employees 28
Omeros Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Omeros reports second quarter 2018 financial results 30
May 10, 2018: Omeros Reports First Quarter 2018 Financial Results 33
Mar 01, 2018: Omeros Reports Fourth Quarter and Year-End 2017 Financial Results 35
Nov 09, 2017: Omeros Reports Third Quarter 2017 Financial Results 37
Aug 08, 2017: Omeros Reports Second Quarter 2017 Financial Results 39
May 10, 2017: Omeros Reports First Quarter 2017 Financial Results 41
Mar 16, 2017: Omeros Reports Fourth Quarter and Year-End 2016 Financial Results 43
Other Significant Developments 45
Apr 11, 2018: Omeros Announces Amendment of Credit Facility 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Omeros Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omeros Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omeros Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Omeros Corp, Medical Devices Deals, 2012 to YTD 2018 9
Omeros Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omeros Acquires Antibody Related Assets from Xori 11
Omeros Enters into Licensing Agreement with Fagron 12
Omeros Raises USD68.3 Million in Public Offering of Shares 13
Omeros Raises USD0.74 Million in Public Offering of Shares 15
Omeros Raises USD37.3 Million in Public Offering of Shares 16
Omeros Raises USD84 Million in Public Offering of Shares and Pre-Funded Warrants 18
Omeros Completes Public Offering Of Shares For US$40.3 Million 20
Omeros Completes Private Placement Of Common Stock For US$16 Million 22
Omeros Announces Public Offering Of Common Stock For US$60 Million 24
Omeros Completes Public Offering Of Common Stock For US$34.5 Million 25
Omeros Corp, Key Competitors 27
Omeros Corp, Key Employees 28
Omeros Corp, Subsidiaries 29

List of Figures
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Omeros Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Omeros Corp (OMER):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mundipharma International Ltd:企業の戦略的SWOT分析
    Mundipharma International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Adamas Pharmaceuticals Inc (ADMS):製薬・医療:M&Aディール及び事業提携情報
    Summary Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company's Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment fo …
  • Sumitomo Electric Industries, Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Electric Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Electric Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Norwegian Air Shuttle ASA:企業の戦略・SWOT・財務情報
    Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report Summary Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Circassia Pharmaceuticals Plc (CIR):製薬・医療:M&Aディール及び事業提携情報
    Summary Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease …
  • Krystal Biotech Inc (KRYS):製薬・医療:M&Aディール及び事業提携情報
    Summary Krystal Biotech Inc (Krystal Biotech) is a drug development company that uses gene therapy to develop novel treatments for skin diseases. The company’s pipeline products include KB103, KB105, and KB200. Its products are used for the treatment of dystrophic EB, TGM1-deficient autosomal recess …
  • QVC Inc:企業の戦略的SWOT分析
    QVC Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • AIT Austrian Institute of Technology GmbH:医療機器:M&Aディール及び事業提携情報
    Summary AIT Austrian Institute of Technology GmbH (AIT) is a research and technology organisation which provides research and development services. The institute provides research and technological development for infrastructure related technologies in the fields of energy, mobility systems, low-emi …
  • Solaris d.d.:企業の戦略・SWOT・財務情報
    Solaris d.d. - Strategy, SWOT and Corporate Finance Report Summary Solaris d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Tyson Foods Inc:企業の戦略・SWOT・財務情報
    Tyson Foods Inc - Strategy, SWOT and Corporate Finance Report Summary Tyson Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • VertiFlex Inc:医療機器:M&Aディール及び事業提携情報
    Summary VertiFlex Inc (Vertiflex) is a medical device company that offers invasive treatments for lumbar stenosis. The company offers products such as interspinous spacer and direct decompression systems. Its interspinous spacer system is a motion-preserving, indirect decompression spinal implant sy …
  • 4imprint Group plc (FOUR):企業の財務・戦略的SWOT分析
    4imprint Group plc (FOUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • NorthWestern Corp:企業の発電所・SWOT分析2018
    NorthWestern Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Under Armour Inc (UAA):企業の財務・戦略的SWOT分析
    Under Armour Inc (UAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • UTair Aviation:企業の戦略・SWOT・財務情報
    UTair Aviation - Strategy, SWOT and Corporate Finance Report Summary UTair Aviation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Veridian Corporation:企業の戦略的SWOT分析
    Veridian Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Ralph Lauren Corp:企業の戦略・SWOT・財務分析
    Ralph Lauren Corp - Strategy, SWOT and Corporate Finance Report Summary Ralph Lauren Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Painted Pony Energy Ltd (PONY):石油・ガス:M&Aディール及び事業提携情報
    Summary Painted Pony Energy Ltd (Painted Pony Energy), formerly Painted Pony Petroleum Ltd is a natural gas producer that offers production development drilling for natural gas and natural gas liquids. The company offers development of its premium, sweet natural gas resource base located in the opti …
  • Gore Mutual Insurance Company:企業の戦略・SWOT・財務情報
    Gore Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Gore Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Exelon Corporation (EXC):電力:M&Aディール及び事業提携情報
    Summary Exelon Corporation (Exelon) is a utility services holding company operating across the energy value chain comprising power generation, distribution, transmission and energy sales. It generates electricity from diverse sources, including nuclear, fossil fuels and renewable energy. Exelon deli …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆